Leiner
This article was originally published in The Tan Sheet
Executive Summary
Gross inventory down $45.4 mil. to $133.9 mil. at second quarter's end compared to prior-year period, reflecting "complexity reduction and supply chain reengineering," company says Nov. 14. Restructuring professional fees and expenses comprised $3.1 mil. of $5.1 mil. in non-recurring expenses for Q2 ended Sept. 30. Sales fell 8% to $151.6 mil. for the quarter, but gross profit as a percentage of sales improved to 21.8% from 21.3% a year ago due to better plant efficiencies, discontinuation of less profitable SKUs. Net loss jumped to $11.9 mil. from $2.6 mil. in prior-year quarter. On Nov. 2, Leiner announced plans to file for Chapter 11 protection in early 2002 (1"The Tan Sheet" Nov. 12, p. 11)...
You may also be interested in...
Leiner Chapter 11 Plan To Include New Capital, Credit, Debt Restructuring
Leiner Health Products will use a tentative $20 mil. equity investment to support ongoing operations as it prepares to seek Chapter 11 protection in early 2002, the company stated
Beauty Firms Using AI-Based Tools Could Be Subject To Health Privacy Laws In US States
Using AI-based programs to collect and store consumer information risks running afoul of new health privacy laws cropping up in US states. Lack of federal regulation or guidance on the issue is one of the biggest challenges for beauty firms deploying AI, according to Stacy Marcus, partner at Reed Smith LLP.
Mustang Bio Enters Race For CAR-T In Autoimmune Disease
The biotech company’s CEO talked to Scrip about plans to bring the CD20-targeting CAR-T MB-106 into an investigator-sponsored Phase I trial later this year.